April 1st Week, 2025 Regulatory Events 🎯 AstraZeneca 's neoadjuvant durvalumab (anti-PD-L1) + chemo followed by adjuvant durvalumab...

March 4th Week, 2025 Regulatory Events 🎯 CStone Pharmaceuticals submitted a Type II variation application to the EMA for sugemalimab...

May 5th & June 1st Week ⭐ Regulatory Updates 🎯 China’s NMPA granted Priority Review to CARsgen Therapeutics ’ satri-cel (CT041; an...

May 3rd Week, 2025 ⭐ Regulatory Update 🎯 The US FDA granted the RMAT designation to BrainChild Bio ’s BCB-276 (an autologous, B7-H3...

May 1st & 2nd Week, 2025 ⭐ Deals & Collaborations 🤝 NKure Therapeutics and CRISPR Therapeutics partnered to co-develop CRISPR’s...

April 2nd April, 2025 ⭐ Regulatory Events 🎯 The US FDA cleared an IND application of CERo Therapeutics, Inc. ’s CER-1236 (anti-Tim-4L...

March 3rd Week, 2025 Regulatory Events 🎯 The European commission granted approval to Bristol Myers Squibb ’ Breyanzi (lisocabtagene...

March 1st Week, 2025 ⭐ Regulatory Events 🎯 China’s NMPA granted Breakthrough Therapy Designation (BTD) to CARsgen Therapeutics ’...

February 4th Week, 2025 📝 The US FDA granted RMAT designation for ImmunityBio ’s Anktiva (n ogapendekin alfa inbakicept; IL-15...

📢 The U.S. FDA launched a new program - the Commissioner’s National Priority Voucher (CNPV) - to shorten review timelines from 10-12...

“The right target, at the right time, for the right price” …is and always has been a guiding principle for Merck KGaA, as stated by its...